Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases

BioDrugs

Volumn 22, Issue 1, 2008, Pages 37-44

  Kharitonenkov, Alexei ^a   Shanafelt, Armen B ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Fibroblast growth factor 21 agonists, general; Fibroblast growth factor, general; Metabolic disorders; Research and development

Indexed keywords

FIBROBLAST GROWTH FACTOR 21;

DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HUMAN; IN VITRO STUDY; INSULIN RESISTANCE; METABOLIC DISORDER; METABOLIC REGULATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

EID: 38549092079     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200822010-00004     Document Type: Review

References (52)

1. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001; 2 (3): 3005.1-12
2. Eswarakumar VP, Lax I, Schlessinger J. Cellular signalling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005 Apr; 16 (2): 139-49
3. Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005 Apr; 16 (2): 179-86
4. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005 Apr; 16 (2): 159-78
5. Sakaue H, Konishi M, Ogawa W, et al. Requirement of fibroblast growth factor 10 in development of white adipose tissue. Genes Dev 2002 Apr; 16 (8): 908-12
6. Bhushan A, Itoh N, Kato S, et al. FGF10 is essential for maintaining the proliferative capacity of epithelial progenitor cells during early pancreatic organogenesis. Development 2001 Dec; 128 (24): 5109-17
7. Konishi M, Micami T, Yamasaki M, et al. Fibroblast growth factor-16 is a growth factor for embryonic brown adipocytes. J Biol Chem 2000 Apr; 275 (16): 12119-22
8. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005 Oct; 2 (4): 217-25
9. Lundåsen T, Gålman C, Angelin B, et al. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006 Dec; 260 (6): 530-6
10. Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002 May; 143 (5): 1741-7
11. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin deficient diabetes. Endocrinology 2004 Jun; 145 (6): 2594-603
12. Yu X, White KE. FGF-23 and disorders of phosphate metabolism. Cytokine Growth Factor Rev 2005 Apr; 16 (2): 221-32
13. Kuro-o M. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 2006 Jul; 15 (4): 437-41
14. Hart AW, Baeza N, Apelqvist A, et al. Attenuation of FGF-signalling in mouse β-cells leads to diabetes. Nature 2000 Dec; 408 (6814): 864-8
15. Revest JM, Spencer-Dene B, Kerr K, et al. Fibroblast growth factor receptor 2 IIIb acts upstream of Shh and FGF4 and is required for limb bud maintenance but not for the induction of FGF8, FGF10, Msx1, or BMP4. Dev Biol 2001 Mar; 231 (1): 47-62
16. Celli G, LaRochelle WJ, Mackem S, et al. Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. EMBO J 1998 Mar; 17 (6): 1642-55
17. Elghazi L, Cras-Meneur C, Czernichow P, et al. Role for FGFR2IIIb-mediated signals in controlling pancreatic endocrine progenitor cell proliferation. Proc Natl Acad Sci U S A 2002 Mar; 99 (6): 3884-9
18. Eswarakumar VP, Schlessinger J. Skeletal overgrowth is mediated by deficiency in a specific fibroblast growth factor receptor 3. Proc Natl Acad Sci 2007 Mar; 104 (10): 3937-42
19. Yu C, Wang F, Jin C, et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 2000 May; 275 (20): 15482-9
20. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005 Jun; 115 (6): 1627-35
21. Nishimura T, Nakatake Y, Konishi M, et al. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000 Jun; 1492 (1): 203-6
22. Zhang X, Ibrahimi OA, Olsen SK, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 2006 Jun; 281 (23): 15694-700
23. Badman MK, Pissios P, Kennedy AR, et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007 Jun; 5 (6): 426-37
24. Huang X, Yu C, Jin C, et al. Forced expression of hepatocyte-specific fibroblast growth factor-21 delays initiation of chemically-induced hepatocarcinogenesis. Mol Carcinog 2006 Dec, 42
25. Wente W, Efanov AM, Brenner M, et al. Fibroblast growth factor-21 improves pancreatic β-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006 Sep; 55 (9): 2470-8
26. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007 Jun; 5 (6): 415-25
27. Ma L, Robinson LN, Towle HC. ChREBP-MLX is the principal mediator of glucose induced gene expression in the liver. J Biol Chem 2006 Sep; 281 (39): 28721-30
28. Stevenson EJ, Koncarevic A, Giresi PG, et al. Transcriptional profile of a myotube starvation model of atrophy. J Appl Physiol 2005 Apr; 98 (4): 1396-406
29. Lundåsen T, Hunt MC, Nilsson LM, et al. PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 2007 Aug; 360 (2): 437-40
30. Boyce K, Kriete A, Nagatomi S, et al. Phenotypical enrichment strategies for microarray data analysis applied in a type II diabetes study. OMICS 2005; 9 (3): 251-65
31. Moyers JS, Shiyanova TL, Mehrbod F, et al. Molecular determinants of FGF-21 activity: synergy and cross-talk with PPARã signaling. J Cell Physiol 2007 Jan; 210 (1): 1-6
32. Goetz R, Beenken A, Ibrahimi OA, et al. Molecular insights into the Klotho-dependent, endocrine mode of action of FGF19 subfamily members. Mol Cell Biol 2007 May; 27 (9): 3417-28
33. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005 Apr; 16 (2): 107-37
34. Ogawa Y, Kurosu H, Yamamoto M, et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A 2007 May 1; 104 (18): 7432-7
35. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007 Feb; 148 (2): 774-81
36. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997 Oct; 91 (2): 231-41
37. Yamauchi H, Hotta Y, Konishi M, et al. FGF21 is essential for haematopoiesis in zebrafish. EMBO Rep 2006 Jun; 7 (6): 649-54
38. Ito S, Kinoshita S, Shiraishi N, et al. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech Dev 2000 Nov; 98 (1-2): 115-9
39. Kuro-o M, Matsumura Y, Arizava H, et al. Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature 1997 Nov; 390 (6655): 45-51
40. Ito S, Fujimori T, Furuya A, et al. Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J Clin Invest 2005 Aug; 115 (8): 2202-8
41. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 2006 Mar; 281 (10): 6120-3
42. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006 Dec; 444 (7120): 770-4
43. Chang Q, Hoefs S, van der Kemp AW, et al. The beta-glucuronidase Klotho hydrolyzes and activates the TRPV5 channel. Science 2005 Oct; 310 (5747): 490-3
44. Shah P, Vella A, Basu A, et al. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000 Nov; 85 (11): 4053-9
45. Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005 Feb; 257 (2): 167-75
46. Kannel WB. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 2005 Dec; 40 (12): 1215-20
47. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006 Jan; 439 (7075): 484-9
48. Kobayashi M, Ikegami H, Fujisawa T, et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007 Jan; 56 (1): 239-47
49. Lefebvre P, Chinetti G, Fruchart JC, et al. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006 Mar; 116 (3): 571-80
50. Kersten S, Seydoux J, Peters JM, et al. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 1999 Jun; 103 (11): 1489-98
51. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 May; 27 (5): 1047-53
52. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001 Dec; 414 (6865): 821-7